Summit Therapeutics Stock Forecast, Price & News

+0.10 (+1.57 %)
(As of 09/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume118,063 shs
Average Volume217,979 shs
Market Capitalization$631.04 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Summit Therapeutics logo

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.16 out of 5 stars

Medical Sector

1172nd out of 1,352 stocks

Pharmaceutical Preparations Industry

570th out of 665 stocks

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

Is Summit Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Summit Therapeutics?

Wall Street analysts have given Summit Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Summit Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a decline in short interest during the month of August. As of August 13th, there was short interest totaling 688,600 shares, a decline of 18.6% from the July 29th total of 845,900 shares. Based on an average daily volume of 219,100 shares, the days-to-cover ratio is presently 3.1 days. Currently, 2.8% of the shares of the stock are sold short.
View Summit Therapeutics' Short Interest

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Summit Therapeutics

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) released its earnings results on Wednesday, August, 11th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.09. Summit Therapeutics had a negative net margin of 350.72% and a negative trailing twelve-month return on equity of 96.34%.
View Summit Therapeutics' earnings history

How has Summit Therapeutics' stock price been impacted by Coronavirus?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SMMT shares have increased by 242.9% and is now trading at $6.48.
View which stocks have been most impacted by COVID-19

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:
  • Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77)
  • Mr. Michael Paul Donaldson, Chief Financial Officer (Age 44, Pay $296.2k)
  • Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51, Pay $459.38k)
  • Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
  • Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
  • Ms. Michelle Avery, Director of Investor Relations
  • Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
  • Ms. Christine Armstrong, VP of Marketing?
  • Mr. Campbell Hair, Head of HR?
  • Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)

Who are some of Summit Therapeutics' key competitors?

What other stocks do shareholders of Summit Therapeutics own?

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.13%), Vanguard Group Inc. (0.90%), Baillie Gifford & Co. (0.45%), State Street Corp (0.26%), Geode Capital Management LLC (0.23%) and Morgan Stanley (0.22%). Company insiders that own Summit Therapeutics stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends for Summit Therapeutics

Which institutional investors are selling Summit Therapeutics stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of America Corp DE, Citigroup Inc., and JPMorgan Chase & Co..
View insider buying and selling activity for Summit Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Summit Therapeutics stock?

SMMT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, Baillie Gifford & Co., Renaissance Technologies LLC, Charles Schwab Investment Management Inc., and Nuveen Asset Management LLC. Company insiders that have bought Summit Therapeutics stock in the last two years include Maky Zanganeh, and Robert W Duggan.
View insider buying and selling activity for Summit Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $6.48.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $631.04 million and generates $20.17 million in revenue each year. The company earns $-52,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 80 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.